Rosemont Pharmaceuticals

About  

Inflexion is backing Rosemont Pharmaceuticals, the UK’s leading oral liquid medicines specialist it carved out from a US-listed parent, to grow through new products, acquisitions and US expansion.

Rosemont supplies essential treatments for patients with swallowing difficulties, primarily elderly and paediatric patients. It is the sole UK supplier of 27 unique molecules, with a portfolio of over 130 oral liquid medicines sold in the UK, the US, continental Europe and the Middle East. Building on its UK leadership, Rosemont has established a US specialty platform, launching its first branded products in 2026, with a focused pipeline in neurology and paediatrics.

Value acceleration  

Since the carve-out, Rosemont has expanded internationally, launched 17 new products and more than doubled its turnover. With substantial experience in executing carve-outs, Inflexion has drawn on its healthcare expertise to establish Rosemont as a fully standalone business, using its digital experience to support the IT carve-out. Inflexion has invested in innovation and new product development to build a focused pipeline across the UK and US, and its talent team has supported a full leadership build-out, including a new CEO, CFO and US President. Rosemont has added in-house development capability through four bolt-ons in the UK, US and Greece. In 2025, Inflexion reinvested in Rosemont to support its next phase of growth.